4‐1BB Delineates Distinct Activation Status of Exhausted Tumor‐Infiltrating CD8 + T Cells in Hepatocellular Carcinoma-Reference-Cited by-同舟云学术

4‐1BB Delineates Distinct Activation Status of Exhausted Tumor‐Infiltrating CD8 + T Cells in Hepatocellular Carcinoma

Published:2019-10-18 Issue:3 Volume:71 Page:955-971
ISSN:0270-9139
Container-title:Hepatology
language:en
Short-container-title:Hepatology

Author:

Kim Hyung‐Don¹,Park Seongyeol¹,Jeong Seongju²,Lee Yong Joon¹,Lee Hoyoung²,Kim Chang Gon¹,Kim Kyung Hwan¹,Hong Seung‐Mo³,Lee Jung‐Yun⁴,Kim Sunghoon⁴,Kim Hong Kwan⁵,Min Byung Soh⁶,Chang Jong Hee⁷,Ju Young Seok¹²,Shin Eui‐Cheol¹²,Song Gi‐Won⁸,Hwang Shin⁸,Park Su‐Hyung¹²^ORCID

Affiliation:

1. Graduate School of Medical Science and Engineering Korea Advanced Institute of Science and Technology Daejeon Republic of Korea

2. Biomedical Science and Engineering Interdisciplinary Program Korea Advanced Institute of Science and Technology Daejeon Republic of Korea

3. Department of Pathology, Asan Medical Center University of Ulsan College of Medicine Seoul Republic of Korea

4. Department of Obstetrics and Gynecology Severance Hospital, Yonsei University College of Medicine Seoul Republic of Korea

5. Department of Thoracic and Cardiovascular Surgery Samsung Medical Center, Sungkyunkwan University School of Medicine Seoul Republic of Korea

6. Department of Surgery Severance Hospital, Yonsei University College of Medicine Seoul Republic of Korea

7. Department of Neurosurgery, Severance Hospital Yonsei University College of Medicine Seoul Republic of Korea

8. Department of Surgery, Asan Medical Center University of Ulsan College of Medicine Seoul Republic of Korea

Funder

National Research Foundation of Korea

Publisher

Wiley

Subject

Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hep.30881

Reference49 articles.

1. Fundamental Mechanisms of Immune Checkpoint Blockade Therapy

2. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

3. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial

4. Targeted and Immune-Based Therapies for Hepatocellular Carcinoma

5. The promise and challenges of immune agonist antibody development in cancer

Cited by 72 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unveiling a novel fusion gene enhances CAR T cell therapy for solid tumors;Molecular Cancer;2024-05-10

2. Increased co-expression of 4-1BB with PD-1 on CD8+ tumor-infiltrating lymphocytes is associated with improved prognosis and immunotherapy response in cervical cancer;Frontiers in Oncology;2024-05-02

3. Anti–4-1BB×PDL1 Bispecific Antibody Reinvigorates Tumor-Specific Exhausted CD8+ T Cells and Enhances the Efficacy of Anti-PD1 Blockade;Clinical Cancer Research;2024-04-30

4. T-cell subsets and cytokines are indicative of neoadjuvant chemoimmunotherapy responses in NSCLC;Cancer Immunology, Immunotherapy;2024-04-15

5. ATG-101 Is a Tetravalent PD-L1×4-1BB Bispecific Antibody That Stimulates Antitumor Immunity through PD-L1 Blockade and PD-L1–Directed 4-1BB Activation;Cancer Research;2024-03-19